Astaria Global
Astaria Global is a Houston-based veterinary health company that sells the patented Alpha2EQ autologous orthobiologic platform — kits that isolate alpha-2-macroglobulin from a horse's own blood to treat lameness, joint inflammation, and airway conditions — exclusively through licensed equine veterinarians.
- Company typePrivate
- Founded-
- HeadquartersHouston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Astaria Global does
Astaria Global is a Houston, Texas-based veterinary health company that develops and commercializes Alpha2EQ, an orthobiologic therapy platform for horses. The company's core technology is the patented AlphaActive filtration process — a two-step centrifugation method that functionally isolates alpha-2-macroglobulin (α2M), a naturally occurring anti-inflammatory protein, from the horse's own blood. This autologous preparation is sold as processing kits (Alpha2EQ-30 multi-dose and Alpha2EQ-15 single-dose) to licensed veterinarians, who administer the resulting injectate on-site for lameness, osteoarthritis, joint inflammation, soft tissue injury, and — via a newer nebulizing application using Flexineb equipment — airway inflammation and equine asthma.
The business model is sales-led and exclusively B2B-to-veterinarian: Alpha2EQ is only available through licensed equine veterinarians, with end customers (horse owners, riders, and trainers) accessing the therapy through their vet. Revenue is generated via one-time unit sales of processing kits and bundled Flexineb nebulizer distribution at practitioner pricing, with pay-as-you-go billing per kit and no disclosed subscription or recurring component. Marketing is veterinarian-centric content marketing supported by scientific resources, protocol signup forms, and phone/email support.
The company operated as a privately held Texas LLC with 1–10 employees and was acquired by Creative Science, a CIMA Animal Health company, on April 25, 2025, to expand Creative Science's equine division. The acquisition positions Astaria Global's orthobiologic technology within a larger animal health platform, though the company retains its own brand, product line, and veterinarian-facing distribution identity.
Astaria Global firmographics
Firmographics- Name
- Astaria Global
- Legal name
- Astaria Global
- Website
- https://astariaglobal.com
- Company type
- Private
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Astaria Global is a Houston-based veterinary health company that sells the patented Alpha2EQ autologous orthobiologic platform — kits that isolate alpha-2-macroglobulin from a horse's own blood to treat lameness, joint inflammation, and airway conditions — exclusively through licensed equine veterinarians.
- Ownership category
- akta.pro rank
Astaria Global industry classification
Industry- Product category
- Equine Orthobiologics
- NAICS
- Veterinary Services (54194)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Equine Therapeutics (Rx) (HLAMAEAC)
- akta.pro secondary industry
- Sports Medicine, Lameness & Performance (Equine) (HLAMABAJ)
Keywords
Where Astaria Global is headquartered
LocationHeadquarters
- HQ city
- Houston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Astaria Global business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations
Revenue model
- Alpha2EQ Orthobiologic Kit Sales: Sale of proprietary multi-dose blood processing kits (Alpha2EQ-30 and Alpha2EQ-15) to veterinarians for use in autologous equine therapy. The kits are sold directly to veterinarians who then administer the therapy to horse owners. Product can be frozen for future use, extending the value per kit across multiple treatments.
- Nebulizer Equipment Sales: Distribution of Flexineb nebulizer devices to veterinary practitioners at practitioner pricing, supporting the nebulizing application of Alpha2EQ for equine airway inflammation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Alpha2EQ-30 (Multi-dose kit for 2+ injection sites) |
| Unit Pricing | Pay-as-you-go | Alpha2EQ-15 (Single-syringe processing kit) |
| Unit Pricing | Pay-as-you-go | Flexineb Nebulizer (Practitioner pricing) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels7 records
Astaria Global product offering
Product offeringCore offering
Astaria Global sells the Alpha2EQ line of autologous orthobiologic therapy kits for horses. Using the patented AlphaActive filtration process, the kits isolate alpha-2-macroglobulin from the horse's own blood on-site at the veterinary clinic. The portfolio includes the Alpha2EQ-30 multi-dose kit (70mL blood volume), the Alpha2EQ-15 single-dose kit (35mL), and a nebulizing formulation for airway inflammation, all targeting equine lameness, osteoarthritis, soft tissue injuries, and equine asthma.
Product overview
Astaria Global offers a unified product portfolio centered on Alpha2EQ, an orthobiologic therapy platform that uses the patented AlphaActive filtration technology to isolate alpha-2-macroglobulin from horses' own blood. The portfolio consists of two processing kit variants—Alpha2EQ-30 (multi-dose, 70mL blood volume) and Alpha2EQ-15 (single-dose, 35mL volume)—for intra-articular injection to address lameness, joint inflammation, and soft tissue injuries, plus a nebulizing formulation for equine airway inflammation and asthma. All products are drug-free, require on-site processing, and leverage the same core AlphaActive filtration mechanism.
Differentiator
Problem solved
Functional benefit
Brands
- Alpha2EQ: Orthobiologic therapy product for equine lameness, joint inflammation, soft tissue injury, and airway inflammation. Powered by the patented AlphaActive filtration process that isolates alpha-2-macroglobulin from horse's own blood.
Products and services
- Alpha2EQ Autologous orthobiologic therapy that isolates alpha-2-macroglobulin from a horse's own blood using the patented AlphaActive filtration process. Addresses equine lameness, joint inflammation, soft tissue injury, and airway inflammation through a potent biological anti-inflammatory molecule. Sold only to licensed veterinarians for in-clinic administration.
- Alpha2EQ-30 Multi-dose processing kit that processes 70mL of blood (two 35mL syringes) into filtered alpha-2-macroglobulin injectate for multi-site use in a single veterinary visit. Excess product can be frozen for up to 12 months. Sold to licensed veterinarians for treatment of equine lameness, osteoarthritis, synovitis, bursitis, and tendon lesions.
- Alpha2EQ-15 Single-dose processing kit that processes 35mL of blood plus 5mL ACD-A anticoagulant into filtered alpha-2-macroglobulin injectate. Designed for smaller-volume applications and reduced dosing needs in equine joint and soft tissue therapy. Sold to licensed veterinarians.
- Alpha2EQ Nebulizing Alpha2EQ formulation delivered via Flexineb nebulizer for the treatment of equine airway inflammation associated with equine asthma. Includes a nebulizing protocol and pilot study data. Sold to licensed veterinarians, with Astaria Global distributing Flexineb nebulizer devices at practitioner pricing for use in administering this therapy.
Quantifiable outcome
- Results of treatment can be observed within a few days of the procedure and may have long-lasting effects of 6–12 months.
- +2 more outcomes
Companies that use Astaria Global
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
Astaria Global technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Astaria Global partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Creative Science (CIMA Animal Health)coreCreative Science, a CIMA Animal Health company, acquired Astaria Global on April 25, 2025. The acquisition aims to enhance Creative Science's equine division, reinforce its leadership in equine veterinary care, and broaden its portfolio of animal health companies. Astaria Global's Alpha2EQ orthobiologic technology complements Creative Science's existing equine health solutions.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Astaria Global competitors and assessment
Company assessmentDirect peers
- Terumo BCT (Harvest): Terumo BCT sells the Harvest PRP system used by equine veterinarians for autologous platelet-rich plasma therapy in joints and soft tissue. It competes in the same on-site processing, blood-derived biologic category as Alpha2EQ.
- Arthrex Vet Systems: Arthrex Vet Systems offers the ACP (Autologous Conditioned Plasma) system for equine joint therapy, the closest direct substitute for Alpha2EQ in the autologous protein injection category. Both companies sell proprietary kits that veterinarians process on-site from the horse's own blood and serve the same equine sports medicine channel.
- EmCyte Corporation: EmCyte manufactures PRP and autologous biologic kits (PurePRP, Concentrated Bone Marrow Aspirate) used in equine and sports medicine. Like Alpha2EQ, it sells kit-based systems that veterinarians process in-clinic from the patient's own blood.
- PulseVet (Zoetis): PulseVet's focused shockwave therapy devices are widely used in equine sports medicine for the same lameness and soft tissue indications Alpha2EQ addresses. Now part of Zoetis, it is a directly competing modality in the equine regenerative and performance-medicine toolkit.
- VetStem Biopharma: VetStem provides autologous stem cell therapy for equine joint and soft tissue injuries, competing head-to-head with Alpha2EQ in the regenerative equine lameness market. Both target performance horse owners and equine veterinarians seeking drug-free biologics.
Broad incumbents
- Zoetis: Zoetis is the largest pure-play animal health company and a broad incumbent in equine pharmaceuticals and biologics. Its portfolio of equine anti-inflammatories, joint therapies, and regenerative offerings (including PulseVet) overlaps with Alpha2EQ's positioning.
- Elanco Animal Health: Elanco (now including the Dechra acquisition) is a top-tier animal health company with a substantial equine product portfolio. It competes broadly for the same equine veterinary prescribing and stocking decisions targeted by Alpha2EQ's vet-channel sales motion.
- Dechra Pharmaceuticals: Dechra specializes in equine endocrinology, dermatology, and orthopedic pharmaceuticals (including joint therapies). It competes with Alpha2EQ as a broader portfolio incumbent selling equine pain and joint management products to the same veterinarian channel.
- Boehringer Ingelheim Animal Health: Boehringer Ingelheim's equine division markets legend/hyaluronic acid joint therapies and a broad portfolio of equine respiratory and orthopedic drugs that compete in the same equine lameness prescribing decisions as Alpha2EQ.
Emerging players
- AniCell Biotech: AniCell Biotech markets amniotic-derived regenerative products for equine joint, soft tissue, and ocular conditions. It is an emerging player focused on a related but different regenerative modality that competes for the same biologic-lameness cases targeted by Alpha2EQ.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Astaria Global social profiles
Digital presenceAstaria Global financial estimates
Financial estimateRevenue estimate
Valuation estimate
Astaria Global leadership team
Management profileNumber of profiles
Profiles1 record
Astaria Global funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Astaria Global M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Astaria Global
What does Astaria Global do?
Astaria Global sells the Alpha2EQ line of autologous orthobiologic therapy kits for horses. Using the patented AlphaActive filtration process, the kits isolate alpha-2-macroglobulin from the horse's own blood on-site at the veterinary clinic. The portfolio includes the Alpha2EQ-30 multi-dose kit (70mL blood volume), the Alpha2EQ-15 single-dose kit (35mL), and a nebulizing formulation for airway inflammation, all targeting equine lameness, osteoarthritis, soft tissue injuries, and equine asthma.
Is Astaria Global a public or private company?
Astaria Global is a private company. It is classified as corporate owned and is currently acquired.
When was Astaria Global founded?
Astaria Global was founded in -1. It employs 1 to 10 people.
Where is Astaria Global based?
Astaria Global is headquartered in Houston, United States, in the North America region.
How does Astaria Global make money?
Two revenue lines are on record. Alpha2EQ Orthobiologic Kit Sales are the primary driver. The others are nebulizer Equipment Sales.
Who are Astaria Global's main competitors?
Direct peers on record are Terumo BCT (Harvest), Arthrex Vet Systems, EmCyte Corporation, PulseVet (Zoetis) and VetStem Biopharma. Broad incumbents are Zoetis, Elanco Animal Health, Dechra Pharmaceuticals and Boehringer Ingelheim Animal Health. AniCell Biotech is listed as an emerging player.
Does Astaria Global have an API?
No public API is recorded for Astaria Global.
What industry is Astaria Global in?
Astaria Global's product category is Equine Orthobiologics. Its primary akta.pro industry code is HLAMAEAC, Equine Therapeutics (Rx), with a secondary code of HLAMABAJ, Sports Medicine, Lameness & Performance (Equine). Its NAICS code is 54194 and its SIC code is 2836.